The Promise of Anti-PD-1 Antibodies in the Future of Cancer Care

Speaker: Jeffrey Weber

Did you know that PD-1 was discovered in 1992? It is present in both, T- and B-cells and targeting the PD-1 pathways showed a clear evidence of clinical activity and a great promise in a vast range of cancer types, in particular the case of melanoma. J. Weber describes the promising future of this class of agents with many biomarkers available to test the clinical efficacy of PD-1 targeting antibodies.

Discussion Points

  • What is the programmed death-1 (PD-1) molecule?
  • What is its role in cancer?
  • What are the currently available anti-PD-1 antibodies available/being tested?
  • Overview of other antibodies available (humanised antibodies; CDLA-4 antibodies...)
  • Areas for future research in this field